Combinations ; See Below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Ltd. | Ltd | mg | 30 | Tablet | per tablet | KES | |
| Didanosine More info | |
|---|---|
| Mode Of Action | Nucleoside reverse transcriptase inhibitors (NRTIs) that are converted by cellular cells? enzymes to active phosporylated metabolites that inhibit viral reverse transcriptase and viral DNA synthesis. |
| Drug Indication | HIV infection in combination with other ARVs. |
| Precautions | Hyperuricaemia, peripheral neuritis, sodium restriction diet, phenylketonuria, monitor complete blood count, differential count, aminotransferases, K+, amylase and triglycerides bimonthly. |
| Contra-Indications | Pregnancy and lactation, severe renal and hepatic dysfunction. |
| Side Effects | GI disturbances diarrhoea, pancreatitis, peripheral neuropathy, dry mouth and taste disturbances, hepatitis, CNS disturbances, alopecia, diabetes mellitus and insipidus. |
| Dosage | 125-200mg orally BD or 400mg OD. |
| Pregnancy Category | Category B2 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Hiv Chemotherapy |